Here are 1-3 brief analogies to describe Olema Pharmaceuticals (OLMA):

• A clinical-stage biotech focused on breast cancer, like an early-stage version of Genentech's (Roche) or Eli Lilly's oncology research arm.
• A specialized pharmaceutical startup aiming to develop major new breast cancer treatments, similar to the dedicated oncology R&D efforts within a large company like Merck or AstraZeneca.
• Developing what could be the next significant breast cancer drug, akin to creating an improved, oral version of an established treatment like AstraZeneca's Faslodex, but still in clinical trials.

• Palazestrant (OP-1250): An oral selective estrogen receptor degrader (SERD) and antagonist currently in clinical development for the treatment of estrogen receptor-positive (ER+), HER2- metastatic breast cancer.
• OLEM-066: A novel, potent, and selective oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in preclinical development for solid tumors.

Olema Pharmaceuticals (symbol: OLMA) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, primarily OP-1250 for metastatic breast cancer.

As a clinical-stage company, Olema Pharmaceuticals does not currently have any commercial products approved for sale on the market. Consequently, the company does not generate revenue from product sales and therefore does not have traditional "major customers" that purchase its products or services.

The company's operations are primarily funded through equity financing and other strategic financial activities rather than through product sales to other companies or individuals.

null

Sean P. Bohen, M.D., Ph.D. President, Chief Executive Officer and Director

Dr. Bohen was appointed President and Chief Executive Officer of Olema Oncology in September 2020. Prior to joining Olema, he served as Executive Vice President of Global Medicines Development and Chief Medical Officer at AstraZeneca from 2015 to 2019, overseeing worldwide product development and clinical programs. Before AstraZeneca, Dr. Bohen spent 13 years at Genentech, where he held various leadership roles, including Senior Vice President, Early Development, Genentech Research and Early Development (gRED), and was responsible for delivering new clinical candidates. He also held positions such as Vice President of Immunology Development and Senior Director of ITGR Exploratory Clinical Development at Genentech. Dr. Bohen is currently a non-executive director of Gyroscope Therapeutics, Ltd. and AltruBio, Inc. He earned his B.S. in bacteriology from the University of Wisconsin-Madison, and an M.D. and Ph.D. in biochemistry from the University of California, San Francisco.

Shane William Charles Kovacs, M.B.A. Chief Operating and Financial Officer

Shane Kovacs was appointed Chief Financial Officer of Olema Oncology in September 2020 and also serves as Chief Operating Officer. He leads the company's financial strategy, accounting, information technology, and human resources functions. Mr. Kovacs brings over 20 years of biotechnology operating experience, with a strong background in capital markets and mergers and acquisitions. Before joining Olema, he was the Chief Business and Financial Officer of BlueRock Therapeutics, LP.

Naseem Zojwalla, M.D. Chief Medical Officer

Dr. Zojwalla serves as the Chief Medical Officer at Olema Pharmaceuticals.

Shawnte M. Mitchell, J.D. Chief Legal Officer and Corporate Secretary

Ms. Mitchell was appointed Chief Legal Officer and Corporate Secretary of Olema Pharmaceuticals in February 2025. She has 20 years of experience advising publicly traded and privately held companies in the healthcare, life sciences, and sustainability industries. Prior to Olema, Ms. Mitchell was Chief Legal Officer at Genomatica, overseeing business transformation, contract negotiations, and compliance. She also served as Executive Vice President, General Counsel, and Corporate Secretary at Zogenix, and as Senior Vice President of Corporate Affairs, Chief Compliance Officer, and Corporate Secretary at Aptevo Therapeutics.

David C. Myles, Ph.D. Chief Development Officer

Dr. Myles is the Chief Development Officer at Olema Pharmaceuticals.

1. Clinical Trial Failure and Regulatory Approval

As a clinical-stage biopharmaceutical company, Olema Pharmaceuticals' success is heavily dependent on the positive outcomes of its clinical trials and subsequent regulatory approvals. The company's lead drug candidate, palazestrant, is currently in late-stage trials for ER+/HER2- breast cancer, with pivotal readouts expected between 2025 and 2028. Key risks include the potential for "binary Phase 3 palazestrant results" and general "clinical trial failures, regulatory delays" for its pipeline candidates. Any setbacks in these trials or difficulties in securing regulatory approvals would significantly impact the company's future prospects and valuation.

2. Competition

Olema operates in a highly competitive landscape for breast cancer treatments, particularly within the selective estrogen receptor degrader (SERD) space. The company faces "competitive pressures" from established pharmaceutical companies like AstraZeneca (with Faslodex), Eli Lilly (with Verzenio), Sanofi (with amcenestrant), and Roche (with giredestrant). The success of competing drugs, such as Roche's giredestrant, which recently reported positive Phase 3 data, can influence market sentiment and recalibrate expectations for Olema's own candidates. The "risk of imitation from other companies developing oral SERDs or other novel endocrine therapies" also poses a challenge to Olema's market position.

3. Financial Health and Dilution

Olema Pharmaceuticals is a clinical-stage company that currently generates zero revenue and reports ongoing losses, which is typical for firms in this stage of development. The company's operations are characterized by high research and development (R&D) costs as it advances its clinical programs. This reliance on external funding creates a "potential for dilution if further capital is needed before commercialization". Recent public offerings to fund its pipeline have already led to "investor concerns about dilution". While the company has reported a strong liquidity position with cash, cash equivalents, and marketable securities, the continued cash burn for R&D necessitates careful financial management to avoid over-reliance on market excitement or further dilution.

The advanced development and potential market entry of competing oral Selective Estrogen Receptor Degraders (SERDs) from larger pharmaceutical companies, notably AstraZeneca's camizestrant (AZD9833) and Eli Lilly's imlunestrant (LY3484356). AstraZeneca's camizestrant, in particular, is further along in clinical development with positive Phase 3 results reported in metastatic breast cancer (SERENA-2) and early breast cancer (SERENA-4), posing a significant threat to the future market opportunity and competitive positioning of Olema Pharmaceuticals' lead candidate, palazestrant (OP-1250), should these competitors secure regulatory approval and establish market presence ahead of or with superior profiles to Olema's product.

Olema Pharmaceuticals (OLMA) primarily focuses on developing therapies for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The company's lead product candidate is palazestrant (OP-1250), an investigational oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) currently in Phase 3 clinical trials for ER+/HER2- metastatic breast cancer.

The addressable market for ER+/HER2- breast cancer is significant. In 2023, the total market size for HR+/HER2- breast cancer across the 7MM (United States, EU5 comprising Germany, France, Italy, Spain, and the United Kingdom, and Japan) was approximately USD 10 billion. This market is projected to grow further by 2034 with the introduction of new therapies. Specifically for palazestrant, its revenue is anticipated to reach an annual total of $686 million by 2036 in the U.S.

Olema Pharmaceuticals also has another product candidate, OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, which is currently in Phase 1 clinical trials for breast cancer and other solid tumors. However, detailed addressable market sizes for OP-3136 are not available at this early stage of development.

Olema Pharmaceuticals (OLMA), a clinical-stage biopharmaceutical company, has several expected drivers of future revenue growth over the next 2-3 years, primarily stemming from the advancement and potential commercialization of its product pipeline.

Here are 4-5 key drivers:

1. Commercialization of Palazestrant (OP-1250) as Monotherapy: Olema's lead product candidate, palazestrant, is an orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) for ER+/HER2- metastatic breast cancer. The pivotal Phase 3 OPERA-01 trial is evaluating palazestrant as a monotherapy, with top-line data anticipated in the second half of 2026 and a potential commercial launch as early as 2027. This represents the most immediate and significant potential revenue stream for the company.
2. Advancement and Potential Approval of Palazestrant in Combination with Ribociclib: Olema is progressing with the pivotal Phase 3 OPERA-02 trial, which will evaluate palazestrant in combination with the CDK4/6 inhibitor ribociclib for frontline ER+/HER2- metastatic breast cancer. The initiation of this trial is on track for the third quarter of 2025. Successful development and approval of this combination therapy would significantly expand palazestrant's market opportunity.
3. Expansion of Palazestrant through Additional Combination Therapies: The company is actively pursuing clinical trial collaborations to explore palazestrant in combination with other agents. For example, Olema has an agreement with Pfizer to evaluate palazestrant plus atirmociclib in a Phase 1b/2 study, which is anticipated to begin in the fourth quarter of 2025. These additional combinations broaden the potential patient population and extend the market reach for palazestrant.
4. Progression of OP-3136 (KAT6 Inhibitor) in Clinical Trials: Olema is developing OP-3136, a novel lysine acetyltransferase 6 (KAT6) inhibitor. The Investigational New Drug (IND) application for OP-3136 received FDA clearance in December 2024, and patients are currently being enrolled in a Phase 1 clinical study. Preclinical data has demonstrated anti-tumor activity in various solid tumor models, including ovarian, non-small cell lung, and prostate cancer, indicating the potential for future expansion beyond breast cancer indications. While earlier in development, the successful progression of OP-3136 builds a foundation for long-term revenue growth.

Share Issuance

• Olema Pharmaceuticals secured a $250 million private placement in December 2024 to support its clinical development programs, including the OPERA-01 and new trials.
• In September 2023, Olema completed a private placement of approximately $130 million of common stock, issuing 13,211,382 shares at a purchase price of $9.84 per share.
• The company's cash flow statements indicate common stock issuances of $275.48 million in fiscal year 2024, $133.42 million in fiscal year 2023, and $1.39 million in fiscal year 2021.

Inbound Investments

• In December 2024, Olema secured a $250 million private placement from various investors to fuel its clinical endeavors, including the pivotal Phase 3 OPERA-02 trial.
• In September 2023, the company announced a combined financing of up to $180 million, which included a $130 million equity private placement led by Paradigm BioCapital Advisors with participation from other institutional investors, and a new senior secured credit facility of up to $50 million provided by Silicon Valley Bank.
• Olema has established clinical collaborations, such as the one with Novartis Pharma AG announced in December 2024, where Novartis will provide ribociclib drug supply for the OPERA-02 trial.

Outbound Investments

• Olema Oncology has not made any investments or acquisitions during the last five years.

Capital Expenditures

• Capital expenditures were approximately $0.16 million in fiscal year 2024, $0.36 million in fiscal year 2022, and $1.58 million in fiscal year 2021.
• Research and development (R&D) expenses, a primary focus for the biopharmaceutical company, were $108.0 million for the full year 2024 and $86.1 million for the full year 2023, as the company continued to advance its clinical pipeline.